Theravance Biopharma, Inc. Current Income Tax Expense (Benefit)
Theravance Biopharma, Inc. (TBPH) reported Current Income Tax Expense (Benefit) of $34.87 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-23
- Theravance Biopharma, Inc. current income tax expense (benefit) for the quarter ending 2019-12-31 was $78.00K.
- Theravance Biopharma, Inc. current income tax expense (benefit) for the quarter ending 2019-09-30 was -$5.60M.
- Theravance Biopharma, Inc. current income tax expense (benefit) for the quarter ending 2019-06-30 was -$200.00K.
- Theravance Biopharma, Inc. current income tax expense (benefit) for the quarter ending 2019-03-31 was -$100.00K.
- Theravance Biopharma, Inc. current income tax expense (benefit) for fiscal 2025 was $34.87M, a 79.96% increase from fiscal 2024.
- Theravance Biopharma, Inc. current income tax expense (benefit) for fiscal 2024 was $19.38M, a 613.18% increase from fiscal 2023.
- Theravance Biopharma, Inc. current income tax expense (benefit) for fiscal 2023 was $2.72M.
- Theravance Biopharma, Inc. current income tax expense (benefit) for fiscal 2022 was -$9.00K.
| Period end | Current Income Tax Expense (Benefit) 3 month | Current Income Tax Expense (Benefit) 6 month | Current Income Tax Expense (Benefit) 9 month | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $34.87M 10-K · filed 2026-03-23 | ||||
| 2024-12-31 | $19.38M 10-K · filed 2026-03-23 | ||||
| 2023-12-31 | $2.72M 10-K · filed 2025-03-07 | -$2.72M 10-K · filed 2024-03-01 | |||
| 2022-12-31 | -$9.00K 10-K · filed 2024-03-01 | $9.00K 10-K · filed 2023-03-01 | |||
| 2021-12-31 | -$151.00K 10-K · filed 2023-03-01 | ||||
| 2020-12-31 | -$8.52M 10-K · filed 2023-03-01 | ||||
| 2019-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$5.52M derived: sum of 2 quarters · filed 2022-02-28 | -$5.72M derived: sum of 3 quarters · filed 2022-02-28 | -$5.22M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$5.60M 10-Q · filed 2019-11-08 | -$5.80M derived: sum of 2 quarters · filed 2019-11-08 | -$5.30M 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | -$200.00K 10-Q · filed 2019-08-05 | -$300.00K 10-Q · filed 2019-08-05 | |||
| 2019-03-31 | -$100.00K 10-Q · filed 2019-05-10 | ||||
| 2018-12-31 | -$10.56M 10-K · filed 2021-02-26 | ||||
| 2017-12-31 | $13.69M 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $10.11M 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | $951.00K 10-K · filed 2018-02-28 | ||||
| 2014-12-31 | $6.36M 10-K · filed 2017-03-01 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-03-11 | ||||
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |